Jeffery S. Weber, MD, PhD

Dr. Weber on the Toxicities Associated With Immunotherapy in Lung Cancer

December 14th 2020

Jeffrey S. Weber, MD, PhD, discusses the toxicities associated with immunotherapy in lung cancer.

Dr. Weber on Unmet Needs in Melanoma

December 9th 2020

Jeffrey S. Weber, MD, PhD, discusses unmet needs in melanoma.

Dr. Weber on the Treatment of LDH-High Melanoma

December 1st 2020

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the melanoma program, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone Health’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses the treatment of lactate dehydrogenase (LDH)–high melanoma.

Dr. Weber on the Evolution of Melanoma Treatment

November 5th 2020

Jeffrey S. Weber, MD, PhD, discusses the evolution of the treatment paradigm in melanoma.

Dr. Weber on Results of the COMBI-AD Trial in Stage III BRAF-Mutant Melanoma

October 28th 2020

Jeffrey S. Weber, MD, PhD, discusses the results of the phase 3 COMBI-AD trial with dabrafenib plus trametinib in patients with resected, stage III BRAF V600E/K–mutant melanoma.

Dr. Weber on Emerging Therapies in Melanoma

August 17th 2020

Jeffrey S. Weber, MD, PhD, discusses emerging therapies in melanoma.

Dr. Weber on Research Efforts Examining Neoadjuvant Approaches in Melanoma

June 23rd 2020

Jeffrey S. Weber, MD, PhD, discusses research efforts examining neoadjuvant approaches in melanoma.

Dr. Weber on Combination Strategies for BRAF-Mutant Melanoma

February 14th 2017

Jeffery S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discusses combination strategies for patients with BRAF-mutant melanoma.

Dr. Jeffery S. Weber on Sequencing of Nivolumab, Ipilimumab in Metastatic Melanoma

October 25th 2016

Jeffery S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discuses the key takeaways from the phase II CheckMate-064 trial, in which patients were randomized to receive either nivolumab followed by ipilimumab followed by nivolumab maintenance therapy, or ipilimumab followed by nivolumab and maintenance therapy with nivolumab.

Dr. Weber on Selecting Immunotherapy for Patients With Melanoma

October 5th 2016

Jeffery S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discusses considering factors when selecting an immunotherapy agent for a patient with melanoma.